about
Flucytosine Pharmacokinetics in a Critically Ill Patient Receiving Continuous Renal Replacement Therapy.Voriconazole pharmacokinetics and pharmacodynamics in children.Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based methodVoriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.Canadian clinical practice guidelines for invasive candidiasis in adults.Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, andDevelopment of inhibitor-directed enzyme prodrug therapy (IDEPT) for prostate cancer.Serum voriconazole level variability in patients with hematological malignancies receiving voriconazole therapyObservational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients.Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation.Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update.Primary antifungal prophylaxis in adult hematopoietic stem cell transplant recipients: current therapeutic concepts.Safety of triazole antifungal drugs in patients with cancer.Comparison of clinical pharmacology of voriconazole and posaconazole.Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics.Travel-related disseminated Penicillium marneffei infection in a renal transplant patient.Voriconazole in clinical practice.Safety of posaconazole.Cryptococcosis as an emerging systemic mycosis in dogs.Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.Therapeutic drug monitoring of anti-infective agents in critically ill patients.Liposomal amphotericin B (AmBisome®) at beginning of its third decade of clinical use.Role of therapeutic drug monitoring of voriconazole in the treatment of invasive fungal infections.Effects of intranasally dosed posaconazole on fungal load and biomarkers in Aspergillus fumigatus infected immunocompromised mice.Successful empirical antifungal therapy of intravenous itraconazole with pharmacokinetic evidence in pediatric cancer patients undergoing hematopoietic stem cell transplantation.Antifungal Efficacy of an Intravenous Formulation Containing Monomeric Amphotericin B, 5-Fluorocytosine, and Saline for Sodium Supplementation.Pharmacokinetics and Relative Bioavailability of Orally Administered Innovator-Formulated Itraconazole Capsules and Solution in Healthy Dogs.Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs.Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview.Bioequivalence of orally administered generic, compounded, and innovator-formulated itraconazole in healthy dogs.Impact of glucuronide interferences on therapeutic drug monitoring of posaconazole by tandem mass spectrometry.Liquid chromatography-tandem mass spectrometry method for simultaneous quantification of four triazole antifungal agents in human plasma.Voriconazole, a safe alternative for treating infections caused by the Chrysosporium anamorph of Nannizziopsis vriesii in bearded dragons (Pogona vitticeps).The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxHow effective is [corrected] the use of DBS and DPS as tools to encourage widespread therapeutic drug monitoring?Alternate-day dosing of itraconazole in healthy adult cats.
P2860
Q33424943-B47F8167-8364-4507-A8FD-23698E76925AQ33577291-5B69A673-2583-443E-B0BE-523F62B5F555Q34108484-49655E52-AF79-4621-B05E-54FE323A9347Q34138276-A897D3D8-9D08-4FB0-BBE6-57DE6EDF8F3EQ34237335-E4F629EF-7BC1-452C-862E-2675EAB1398CQ34309603-AA06ECA0-73DA-4C80-AFAE-BB9F8E85BCE3Q34343529-0A2C024D-9999-4478-9424-059BF93AFAD8Q34413393-73FF24E2-2C34-4CD9-968D-EF86C257DB58Q35270270-B8F56484-DC5D-4AFC-835A-66EE17A27972Q36018743-4F4B289A-38E8-4E52-86BA-79300E2FDA9CQ36608562-D0496881-D551-48DB-A52C-30D4B727837AQ37190736-AC45FBA3-B5C4-4973-B67D-21C54AAB8830Q37328834-03E937C1-DA00-40C8-A0A8-443F8E86E11BQ37404840-58E3F477-306B-4216-90AD-4DCE316C207AQ37621550-5AC6670C-BA32-4391-80B6-F57A63A5F32EQ37662650-8CFE26D2-E41B-4616-9BB7-89F7E4E4410FQ37727651-4103611D-ADFE-4D91-8DA2-5C2E601CED51Q37904672-740942B8-48F7-4650-B8FB-8AC318DC648EQ37970481-8372BB16-776D-4004-90DC-4E7186AFD3F9Q38061736-C476A78B-A693-4375-B298-B8438D9A6B01Q38077591-9A90531A-AB79-473B-B69B-911BF0DA0A73Q38131855-55AB10DD-AE53-48AB-ABFC-1D93701FC647Q38193337-B62E6BA6-CF6E-4A73-A20E-62186D4A9694Q38681635-F33CA1A2-6B78-40C2-8BDC-2835383ADA17Q38790740-4A3CB623-A281-42E5-A612-AB5607AE28DBQ39196802-E5B313F1-D29D-4CC7-ABD5-ADBF6F7183DAQ39215244-27665475-82A7-449C-9291-71E12E1030F9Q40138687-74FDC063-F72D-4E7B-B96B-64C086F912A5Q40153913-CAC3EF49-43C4-4D5B-A502-7FB2FD565A9AQ40330676-01269799-CEE3-44C1-BBDC-98F1AC89BF22Q41001936-F197DB57-EBA0-4BB9-B665-90802FCCFB8EQ42217729-924DBA4B-1E1E-477C-B962-E348E32F356EQ42413286-50FF3231-0FC7-4E03-9F6A-794742F81311Q42739321-76D5DC06-E5DB-4FA5-A3D2-AB3A6FA6B239Q42939581-8716A835-EA05-49F8-8FF4-AACA5B545B2CQ43015024-165FA473-95E6-44FF-A71B-85E583859E43Q43108554-3940BEBA-3398-4619-893C-EBA8C6374564Q43600554-EB035A02-0B99-4463-9AFD-FC909AF86DD4Q44748393-10FADE3D-510D-45FA-BB24-0AD9BEEE3793Q44856929-98BDFDA7-BE4B-48C9-893D-EE2EAE83C00A
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Antifungal serum concentration monitoring: an update.
@en
Antifungal serum concentration monitoring: an update.
@nl
type
label
Antifungal serum concentration monitoring: an update.
@en
Antifungal serum concentration monitoring: an update.
@nl
prefLabel
Antifungal serum concentration monitoring: an update.
@en
Antifungal serum concentration monitoring: an update.
@nl
P356
P1476
Antifungal serum concentration monitoring: an update.
@en
P2093
Megan L Goodwin
Richard H Drew
P356
10.1093/JAC/DKM389
P407
P577
2007-11-12T00:00:00Z